ARS Pharmaceuticals Inc (NAS:SPRY)
$ 12.96 0.15 (1.17%) Market Cap: 1.26 Bil Enterprise Value: 1.04 Bil PE Ratio: 0 PB Ratio: 5.77 GF Score: 22/100

Silverback Therapeutics Inc and ARS Pharmaceuticals Inc Merger Announcement Call Transcript

Jul 21, 2022 / 09:00PM GMT
Operator

Good afternoon, everyone, and thank you for joining us today. (Operator Instructions) As a reminder, this conference call is being recorded.

I would now like to turn the call over to Miguel Arcinas, Vice President, Corporate Development and Investor Relations of the Silverback Therapeutics.

Miguel Arcinas
Silverback Therapeutics, Inc. - VP, Corporate Development & IR

Thank you and good afternoon. Joining me on today's call from the Silverback team are Laura Shawver, Chief Executive Officer; Valerie Odegard, President and Chief Scientific Officer; and Jonathan Piazza, Chief Financial Officer. From the ARS Pharma team, we have Richard Lowenthal, Chief Executive Officer; Sarina Tanimoto, Chief Medical Officer; Eric Karas, Chief Commercial Officer; Kathy Scott, Chief Financial Officer; and Justin Chakma, Chief Business Officer.

The recording and the slides presented during this call will be available on the Investor Relations section of Silverback's website and the news section of ARS's website for 30 days.

Before I start, I would

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot